文献速递胸部肿瘤

非小细胞肺癌的一线免疫治疗

First-Line Immunotherapy for Non-Small-Cell Lung Cancer.
PubMed 文献 · J Clin Oncol · 2022-01-05

转移性非小细胞肺癌(mNSCLC)过去十年因抗PD-1、PD-L1及CTLA-4抗体等免疫检查点抑制剂的应用而生存显著改善。除携带可靶向致癌基因者外,几乎所有mNSCLC患者一线接受PD-1或PD-L1治疗。本文报告mNSCLC一线免疫治疗现状及为个体患者选择最佳免疫治疗方案的当前挑战。

要点

  • 抗PD-1、PD-L1及CTLA-4抗体在mNSCLC一线或二线治疗中使部分患者获得前所未有的生存延长。
  • 除携带可靶向致癌基因的mNSCLC外,几乎所有mNSCLC患者一线接受PD-1或PD-L1治疗。
  • 当前挑战在于为个体患者选择最佳的免疫治疗策略。

核心结论

  • mNSCLC一线免疫治疗已取得关键进展,显著改善生存,但为个体患者选择最佳免疫治疗方案仍面临挑战。

研究设计与样本

  • 本文为综述,报告mNSCLC一线免疫治疗的当前状态及当前挑战。

主要发现

  • 针对PD-1、PD-L1及CTLA-4的特定抗体在mNSCLC一线或二线治疗策略中的应用,使部分患者获得前所未有的生存延长。
  • 抗PD-1和PD-L1治疗的临床开发最初主要在二线以单药开始,近期进展转向一线联合方案及将免疫治疗整合入更早期阶段的临床范式。
  • 目前,除携带可靶向致癌基因的mNSCLC外,几乎所有mNSCLC患者一线接受PD-1或PD-L1治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

For patients with metastatic non-small-cell lung cancer (mNSCLC), the last decade has been characterized by critical progress that has contributed to substantially improved survival. In particular, the development of specific antibodies against the programmed death (PD-1) receptor, programmed death-ligand 1 (PD-L1), and the cytotoxic T-lymphocyte-associated protein 4 receptor in the therapeutic strategy of mNSCLC either in first- or in second-line settings have led to unprecedented prolonged survival for a proportion of these patients. Although clinical development of immune checkpoint inhibitors with anti-PD-1 and PD-L1 therapies largely began as monotherapy in the second-line setting, the more recent progress has shifted toward combination approaches in first-line settings as well as the integration of immunotherapy into the clinical paradigm in earlier stages. Today, with the exception of mNSCLC harboring targetable oncogenes, nearly all patients with mNSCLC receive PD-1 or PD-L1 therapy in first-line settings. Here we report the current status of first-line immunotherapy in mNSCLC together with current challenges in selecting the best immunotherapeutic approach for the individual patient.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Reck M, Remon J, Hellmann MD, et al. First-Line Immunotherapy for Non-Small-Cell Lung Cancer. J Clin Oncol. 2022. PMID: 34985920. doi:10.1200/JCO.21.01497

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。